Ginkgo biloba extract, a possible aromatase inhibitor in breast cancer

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SAT 292-325-Breast & Prostate Cancer
Saturday, June 15, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SAT-315
Yong Joo Park*1, Sol Park1, Kyu Hyuck Chung1 and Seung Min Oh2
1Sungkyunkwan University, Suwon, South Korea, 2Hoseo University, Asan, South Korea
Estrogen is an important hormone in regulating the female reproductive system and also key hormone that stimulates the growth of hormone-dependent breast cancer. Cytochrome P450 aromatase (CYP19) is a responsible enzyme for the key step in the biosynthesis of estrogen. Increased CYP19 expression has been considered important cause of breast cancer and lowing aromatase expression was reported to prevent breast cancer. In previous study, we tested possibility of Ginkgo biloba extracts (GBE) as an aromatase inhibitor in JEG-3 cells. GBE is widely used phytomedicines and it has been used as a platelet activating factor, circulatory stimulant and anti-inflammatory drugs. In this study, we tested inhibition effects of GBE and its major components on aromatase activity in aromatase overexpressed human breast cancer cell line (MCF-7 AROM). In MCF-7 AROM cells, GBE (250µg/ml) inhibited 54% of aromatase activity compare to non-treating group. Major active compounds (Quercetin, Kaempferol, and Isorhamnetin) were tested in MCF-7 AROM cells and kaempferol showed most strong aromatase inhibitory effect. Kaempferol inhibited 83% of aromatase activity compare to non-treating group. The decrease of aromatase activity was accompanied by decreasing CYP19 mRNA levels. We suggest that GBE inhibited aromatase activity and it can be possible medicine for prevention and treatment of breast cancer.

Nothing to Disclose: YJP, SP, KHC, SMO

*Please take note of The Endocrine Society's News Embargo Policy at

Sources of Research Support: National Research Foundation of Korea funded by238 the Korean government (MEST)